Healthcare Industry News: protein therapeutics
News Release - December 4, 2007
VistaGen Names Agustin de la Calle, Ph.D. as Vice President, Business DevelopmentSOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--VistaGen Therapeutics, Inc. has named Agustin de la Calle, Ph.D. as Vice President, Business Development. VistaGen is a platform-enabled biopharmaceutical company applying leading-edge embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders.
Prior to joining VistaGen, Dr. de la Calle was head of business development at Innate Pharma, SA (Marseille, France - NYSE Euronext Paris: IPH), director of business development at Micromet AG (Munich, Germany) and manager of business development at Exelixis, Inc. (Nasdaq: EXEL ). Previously in his career he also served as a senior analyst with The Mendel Group (Redwood City, CA), and as a protein scientist at EOS Biotechnology (South San Francisco, CA). Educated at the Freie Universitat Berlin (B.S., M.S., Ph.D.), Dr. de la Calle performed his graduate research at Harvard Medical School and postdoctoral research at the Massachusetts Institute of Technology.
“Agustin’s significant expertise in new technology alliances is a strong fit with the large pharma partnering model we are executing with our embryonic stem cell platform technologies,” said H. Ralph Snodgrass, Ph.D., VistaGen’s President and CEO. “His multi-lingual fluency and extensive scientific and international business background position him to make substantial contributions to our team as we accelerate our emphasis on additional drug discovery and development collaboration opportunities worldwide,” Dr. Snodgrass noted.
VistaGen Therapeutics, Inc. is an emerging biopharmaceutical technology leader applying patented embryonic stem cell technologies for predictive toxicology screening and to discover, develop and commercialize new drug and protein therapies for diabetes and neurological disorders, including neuropathic pain, Parkinson’s disease and epilepsy. Founded in California in 1998, VistaGen discovers and develops drugs and protein biologics for its own pipeline through internal programs and collaborations with leading research organizations. VistaGen also leverages its proprietary embryonic stem cell technology platform through strategic collaborations with leading pharmaceutical and biotechnology companies. More information at www.vistagen.com
Source: VistaGen Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.